Imacure ImatiSYM 100 Tablet contains Imatinib mesylate 100 mg, a tyrosine kinase inhibitor used primarily in the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and other malignancies characterized by specific genetic mutations. Imatinib mesylate functions by selectively inhibiting the BCR-ABL tyrosine kinase, a constitutively active enzyme produced by the Philadelphia chromosome abnormality in CML, thereby blocking the proliferation of leukemic cells. Additionally, it inhibits other tyrosine kinases such as c-KIT and PDGF receptors, contributing to its efficacy in GIST and other tumors. Imacure ImatiSYM 100 is indicated for newly diagnosed Philadelphia chromosome-positive CML in chronic phase, accelerated phase, or blast crisis, as well as for patients resistant or intolerant to prior therapy. The drug is administered orally, with dosing individualized based on disease type, phase, and patient response. Common adverse effects include edema, nausea, muscle cramps, rash, and myelosuppression; therefore, regular monitoring of blood counts and liver function tests is recommended during therapy. Imacure ImatiSYM 100 should be used under strict medical supervision with appropriate diagnostic confirmation and ongoing assessment to optimize therapeutic outcomes and minimize potential toxicities.